Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
MONDAY, JUNE 29, 2026
08:30 - 09:30
REGISTRATION AND MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:10
RESERVED PRESENTATION
10:10 - 10:40
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues – don't forget your business cards!
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON PHARMA OMICS AND AI
11:30 - 11:55
IMPLEMENTATION OF AI IN GxP AREAS OF PHARMA
Loganathan Kumarasamy
Zifo

Loganathan Kumarasamy

Zifo

  • Defining AI implementation in GMP and GCP, from model intent to controlled use in practice
  • Detailing key steps and critical success factors, including EU Annex 22 expectations
  • Readying audit evidence with validation, documentation, and field-tested use case lessons
11:55 - 12:00
Q&A SESSION ON AI IMPLEMENTATION FOR GxP IN PHARMA
12:00 - 13:30
NETWORKING LUNCH AND VISITING THE PHARMA OMICS & AI EXHIBITION
13:30 - 13:55
FULLY-CONNECTED CONTINUOUS MANUFACTURING: UNLOCKING EFFICIENCY AND QUALITY THROUGH AI/ML
Kumar Bala
Enzene Biosciences Ltd.

Kumar Bala

Enzene Biosciences Ltd.

  • Optimizing real-time quality with PAT sensors and analytics to catch deviations early
  • Monitoring connected unit operations continuously, adjusting parameters to protect yield and CQAs
  • Predicting downtime with AI-driven maintenance signals to reduce failures and keep flow steady
  • Streamlining scale-up choices using ML to identify bottlenecks, improve throughput, and compliance
13:55 - 14:00
Q&A SESSION ON AI/ML FOR CONTINUOUS MANUFACTURING
14:00 - 14:25
MAKING MULTI-OMICS ACTIONABLE AT SCALE: THE MMRF MULTIPLE MYELOMA DATA COMMONS, CLINICAL–GENOMIC VISUALIZATION, AND AI/ML-ENABLING DATA FOUNDATIONS
Alexander Gout
Multiple Myeloma Research Foundation

Alexander Gout

Multiple Myeloma Research Foundation

  • Linking CoMMpass multi-omics to longitudinal outcomes across patients for scalable integration
  • Supporting biomarker discovery and hypothesis generation with translational insight from CoMMpass
  • Enabling cohort exploration via clinical–genomic dashboards for stratification and outcome signals
  • Scaling AI/ML-ready omics with harmonization, QC, metadata governance, and cloud reproducibility
14:25 - 14:30
Q&A SESSION ON MAKING MULTI-OMICS ACTIONABLE AT SCALE
14:30 - 14:55
LEVERAGING AI-DRIVEN MULTI-OMICS INTEGRATION TO DECIPHER DISEASE MECHANISMS AND ACCELERATE BIOMARKER DISCOVERY
Ashok Kumar Sharma
Cedars-Sinai Medical Center

Ashok Kumar Sharma

Cedars-Sinai Medical Center

  • Integrating genomics, transcriptomics, and metabolomics to reveal host–microbiome mechanisms
  • Identifying biomarkers with ML models for classification, clustering, and outcome prediction
  • Accelerating drug discovery with AI for toxicology, target finding, and off-target risk mitigation
14:55 - 15:00
Q&A SESSION ON AI-DRIVEN MULTI-OMICS AND BIOMARKERS
15:00 - 15:30
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:30 - 16:00
RESERVED PRESENTATION
16:00 - 17:00
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, JUNE 30, 2026
09:00 - 09:30
MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
FROM R&D TO CLINICAL TRIALS IN ONE LANDSCAPE – HOW AI HAS CLOSED THE GAP
Heather Bowling
Epistemic AI

Heather Bowling

Epistemic AI

  • Exploring how AI expedites multi-omics analysis for biomarker and target discovery
  • Reviewing how AI has changed clinical trial trend analysis, drawing on an NRDD paper
  • Assessing how AI reshapes the competitive landscape and accelerates new drugs via a case study
10:05 - 10:10
Q&A SESSION ON AI CONNECTING R&D AND CLINICAL TRIALS
10:10 - 10:35
BRIDGING MULTI-OMICS AND FUNCTIONAL PRECISION MEDICINE WITH AI — OLD AND NEW: A SUPPORT VECTOR MACHINE FRAMEWORK FOR PREDICTING DRUG RESPONSE FROM PATIENT MOLECULAR PROFILES
Alan Hauser
Health Discovery Corporation

Alan Hauser

Health Discovery Corporation

  • Closing the gap between ex vivo functional assays and scalable multi-omics for drug choice guidance
  • Selecting compact molecular proxies using SVM-RFE to capture functional drug response signals
  • Predicting Venetoclax sensitivity in BeatAML2 with transcriptomics paired to ex vivo sensitivity data
10:35 - 10:40
Q&A SESSION ON PREDICTING DRUG RESPONSE WITH SVM-RFE AND MULTI-OMICS
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:25
DATA OVER HYPE: THE REAL ENGINE OF AGI IN BIOTECH
Sameer Adtani
Benovymed Healthcare Group

Sameer Adtani

Benovymed Healthcare Group

  • Reframing discovery from reactive screening to predictive, automated, systems-level development
  • Generating molecules with foundation models and using self-driving labs for closed-loop testing
  • Linking multi-omics at scale to uncover disease drivers beyond human analysis capacity
  • Elevating data quality and connected CloudLAB records as the primary limiter of AI impact
11:25 - 11:30
Q&A SESSION ON AI, DATA QUALITY, AND SELF-DRIVING DISCOVERY
11:30 - 11:55
A HIGHLY COST-EFFECTIVE PLATFORM FOR CFDNA METHYLOME SEQUENCING AND ITS VERSATILE APPLICATIONS
Jasmine Zhou
EarlyDiagnostics, Inc

Jasmine Zhou

EarlyDiagnostics, Inc

  • Developing an ultra-cost-effective platform for cfDNA methylome sequencing at scale
  • Demonstrating versatile applications for detecting and monitoring multiple diseases over time
  • Validating performance in multi-site blinded studies for early-stage liver cancer detection
  • Extending platform use into drug development workflows, from stratification to response monitoring
11:55 - 12:00
Q&A SESSION ON cfDNA METHYLOME SEQUENCING APPLICATIONS
12:00 - 12:25
REIMAGINING REGULATORY SUBMISSIONS IN THE AGE OF AI
Ahmed Al-Shehab
Phizenix

Ahmed Al-Shehab

Phizenix

  • Identifying low-risk submission tasks where AI can support authoring, reuse, and review
  • Distinguishing assistive uses from validated AI, clarifying when controls and evidence are needed
  • Automating eCTD checks, metadata validation, and traceability to strengthen first-pass quality
12:25 - 12:30
Q&A SESSION ON LOW-RISK AI FOR REGULATORY SUBMISSIONS
12:30 - 12:45
FEEDBACK AND RAFFLE DRAW
12:45 - 14:00
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.